APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Lorlatinib

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Lorlatinib Market Outlook and Growth Opportunities 2026

Report ID 174009020423 December 2025196 pages

Choose your research edition.

Industry ResearchLorlatinib Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Lorlatinib Industry Growth and Trends Forecast to 203270 pages · $3,450 USDMarket StructureGlobal Lorlatinib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032173 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lorlatinib Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Lorlatinib Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Lorlatinib market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Lorlatinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lorlatinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lorlatinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Lorlatinib market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Lorlatinib market include Pfizer. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Lorlatinib market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lorlatinib and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lorlatinib sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Lorlatinib market size, projected growth trends, production technologies, key applications, and end-use industries.

Lorlatinib Segment by Company

Pfizer

Lorlatinib Segment by Type

Tables 25mg

Tables 100mg

Lorlatinib Segment by Application

Adenocarcinoma of NSCLC

Squamous Cell Carcinoma of NSCLC

Large Cell Carcinoma of NSCLC

Lorlatinib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Lorlatinib status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Lorlatinib market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Lorlatinib significant trends, drivers, influence factors in global and regions.

6. To analyze Lorlatinib competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lorlatinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lorlatinib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lorlatinib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Lorlatinib market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Lorlatinib industry.

Chapter 3: Detailed analysis of Lorlatinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Lorlatinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Lorlatinib in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Lorlatinib Industry Trends Table 2. Lorlatinib Industry Drivers Table 3. Lorlatinib Industry Opportunities and Challenges Table 4. Lorlatinib Industry Restraints Table 5. Global Lorlatinib Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Lorlatinib Revenue Share by Company (2021-2026) Table 7. Global Lorlatinib Sales Volume by Company (k pcs) & (2021-2026) Table 8. Global Lorlatinib Sales Volume Share by Company (2021-2026) Table 9. Global Lorlatinib Average Price (US$/pcs) of Company (2021-2026) Table 10. Global Lorlatinib Company Ranking, (2024-2026) & (USD Million) Table 11. Global Lorlatinib Key Company Manufacturing Base & Headquarters Table 12. Global Lorlatinib Company, Product Type & Application Table 13. Global Lorlatinib Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Lorlatinib by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Tables 25mg Table 18. Significant Companies of Tables 100mg Table 19. Global Lorlatinib Sales Volume by Type 2021 VS 2025 VS 2032 (k pcs) Table 20. Global Lorlatinib Sales Volume by Type (2021-2026) & (k pcs) Table 21. Global Lorlatinib Sales Volume by Type (2027-2032) & (k pcs) Table 22. Global Lorlatinib Sales Volume Share by Type (2021-2026) Table 23. Global Lorlatinib Sales Volume Share by Type (2027-2032) Table 24. Global Lorlatinib Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Lorlatinib Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Lorlatinib Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Lorlatinib Sales Value Share by Type (2021-2026) Table 28. Global Lorlatinib Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Adenocarcinoma of NSCLC Table 30. Significant Companies of Squamous Cell Carcinoma of NSCLC Table 31. Significant Companies of Large Cell Carcinoma of NSCLC Table 32. Global Lorlatinib Sales Volume by Application 2021 VS 2025 VS 2032 (k pcs) Table 33. Global Lorlatinib Sales Volume by Application (2021-2026) & (k pcs) Table 34. Global Lorlatinib Sales Volume by Application (2027-2032) & (k pcs) Table 35. Global Lorlatinib Sales Volume Share by Application (2021-2026) Table 36. Global Lorlatinib Sales Volume Share by Application (2027-2032) Table 37. Global Lorlatinib Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Lorlatinib Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Lorlatinib Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Lorlatinib Sales Value Share by Application (2021-2026) Table 41. Global Lorlatinib Sales Value Share by Application (2027-2032) Table 42. Global Lorlatinib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Table 43. Global Lorlatinib Sales by Region (2021-2026) & (k pcs) Table 44. Global Lorlatinib Sales Market Share by Region (2021-2026) Table 45. Global Lorlatinib Sales by Region (2027-2032) & (k pcs) Table 46. Global Lorlatinib Sales Market Share by Region (2027-2032) Table 47. Global Lorlatinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Lorlatinib Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Lorlatinib Sales Value Share by Region (2021-2026) Table 50. Global Lorlatinib Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Lorlatinib Sales Value Share by Region (2027-2032) Table 52. Global Lorlatinib Market Average Price (US$/pcs) by Region (2021-2026) Table 53. Global Lorlatinib Market Average Price (US$/pcs) by Region (2027-2032) Table 54. Global Lorlatinib Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Table 55. Global Lorlatinib Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Lorlatinib Sales by Country (2021-2026) & (k pcs) Table 57. Global Lorlatinib Sales Market Share by Country (2021-2026) Table 58. Global Lorlatinib Sales by Country (2027-2032) & (k pcs) Table 59. Global Lorlatinib Sales Market Share by Country (2027-2032) Table 60. Global Lorlatinib Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Lorlatinib Sales Value Market Share by Country (2021-2026) Table 62. Global Lorlatinib Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Lorlatinib Sales Value Market Share by Country (2027-2032) Table 64. Pfizer Company Information Table 65. Pfizer Business Overview Table 66. Pfizer Lorlatinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 67. Pfizer Lorlatinib Product Portfolio Table 68. Pfizer Recent Development Table 69. Key Raw Materials Table 70. Raw Materials Key Suppliers Table 71. Lorlatinib Distributors List Table 72. Lorlatinib Customers List Table 73. Research Programs/Design for This Report Table 74. Authors List of This Report Table 75. Secondary Sources Table 76. Primary Sources List of Figures Figure 1. Lorlatinib Product Image Figure 2. Global Lorlatinib Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lorlatinib Sales Value (2021-2032) & (US$ Million) Figure 4. Global Lorlatinib Sales (2021-2032) & (k pcs) Figure 5. Global Lorlatinib Sales Average Price (US$/pcs) & (2021-2032) Figure 6. Global Lorlatinib Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Tables 25mg Image Figure 10. Tables 100mg Image Figure 11. Global Lorlatinib Sales Volume by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 12. Global Lorlatinib Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Lorlatinib Sales Volume Share by Type (2021-2032) Figure 14. Global Lorlatinib Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Lorlatinib Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Lorlatinib Sales Value Share by Type (2021-2032) Figure 17. Adenocarcinoma of NSCLC Image Figure 18. Squamous Cell Carcinoma of NSCLC Image Figure 19. Large Cell Carcinoma of NSCLC Image Figure 20. Global Lorlatinib Sales Volume by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 21. Global Lorlatinib Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Lorlatinib Sales Volume Share by Application (2021-2032) Figure 23. Global Lorlatinib Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Lorlatinib Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Lorlatinib Sales Value Share by Application (2021-2032) Figure 26. Global Lorlatinib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Figure 27. Global Lorlatinib Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Lorlatinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Lorlatinib Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Lorlatinib Sales Value (2021-2032) & (US$ Million) Figure 31. North America Lorlatinib Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Lorlatinib Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Lorlatinib Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Lorlatinib Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Lorlatinib Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Lorlatinib Sales Value (2021-2032) & (US$ Million) Figure 37. South America Lorlatinib Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Lorlatinib Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Lorlatinib Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Lorlatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Lorlatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Lorlatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Lorlatinib Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Lorlatinib Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Tables 25mg
  • Tables 100mg
Applications
  • Adenocarcinoma of NSCLC
  • Squamous Cell Carcinoma of NSCLC
  • Large Cell Carcinoma of NSCLC
Companies covered
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Lorlatinib Sales Value (2021-2032)
  4. 1.2.2 Global Lorlatinib Sales Volume (2021-2032)
  5. 1.2.3 Global Lorlatinib Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Lorlatinib Market Dynamics
  1. 2.1 Lorlatinib Industry Trends
  2. 2.2 Lorlatinib Industry Drivers
  3. 2.3 Lorlatinib Industry Opportunities and Challenges
  4. 2.4 Lorlatinib Industry Restraints
3 Lorlatinib Market by Company
  1. 3.1 Global Lorlatinib Company Revenue Ranking in 2025
  2. 3.2 Global Lorlatinib Revenue by Company (2021-2026)
  3. 3.3 Global Lorlatinib Sales Volume by Company (2021-2026)
  4. 3.4 Global Lorlatinib Average Price by Company (2021-2026)
  5. 3.5 Global Lorlatinib Company Ranking (2024-2026)
  6. 3.6 Global Lorlatinib Company Manufacturing Base and Headquarters
  7. 3.7 Global Lorlatinib Company Product Type and Application
  8. 3.8 Global Lorlatinib Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Lorlatinib Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Lorlatinib Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Lorlatinib Market by Type
  1. 4.1 Lorlatinib Type Introduction
  2. 4.1.1 Tables 25mg
  3. 4.1.2 Tables 100mg
  4. 4.2 Global Lorlatinib Sales Volume by Type
  5. 4.2.1 Global Lorlatinib Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Lorlatinib Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Lorlatinib Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Lorlatinib Sales Value by Type
  9. 4.3.1 Global Lorlatinib Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Lorlatinib Sales Value by Type (2021-2032)
  11. 4.3.3 Global Lorlatinib Sales Value Share by Type (2021-2032)
5 Lorlatinib Market by Application
  1. 5.1 Lorlatinib Application Introduction
  2. 5.1.1 Adenocarcinoma of NSCLC
  3. 5.1.2 Squamous Cell Carcinoma of NSCLC
  4. 5.1.3 Large Cell Carcinoma of NSCLC
  5. 5.2 Global Lorlatinib Sales Volume by Application
  6. 5.2.1 Global Lorlatinib Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Lorlatinib Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Lorlatinib Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Lorlatinib Sales Value by Application
  10. 5.3.1 Global Lorlatinib Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Lorlatinib Sales Value by Application (2021-2032)
  12. 5.3.3 Global Lorlatinib Sales Value Share by Application (2021-2032)
6 Lorlatinib Regional Sales and Value Analysis
  1. 6.1 Global Lorlatinib Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lorlatinib Sales by Region (2021-2032)
  3. 6.2.1 Global Lorlatinib Sales by Region: 2021-2026
  4. 6.2.2 Global Lorlatinib Sales by Region (2027-2032)
  5. 6.3 Global Lorlatinib Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Lorlatinib Sales Value by Region (2021-2032)
  7. 6.4.1 Global Lorlatinib Sales Value by Region: 2021-2026
  8. 6.4.2 Global Lorlatinib Sales Value by Region (2027-2032)
  9. 6.5 Global Lorlatinib Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Lorlatinib Sales Value (2021-2032)
  12. 6.6.2 North America Lorlatinib Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Lorlatinib Sales Value (2021-2032)
  15. 6.7.2 Europe Lorlatinib Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Lorlatinib Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Lorlatinib Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Lorlatinib Sales Value (2021-2032)
  21. 6.9.2 South America Lorlatinib Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Lorlatinib Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Lorlatinib Sales Value Share by Country, 2025 VS 2032
7 Lorlatinib Country-level Sales and Value Analysis
  1. 7.1 Global Lorlatinib Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Lorlatinib Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Lorlatinib Sales by Country (2021-2032)
  4. 7.3.1 Global Lorlatinib Sales by Country (2021-2026)
  5. 7.3.2 Global Lorlatinib Sales by Country (2027-2032)
  6. 7.4 Global Lorlatinib Sales Value by Country (2021-2032)
  7. 7.4.1 Global Lorlatinib Sales Value by Country (2021-2026)
  8. 7.4.2 Global Lorlatinib Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Lorlatinib Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Lorlatinib Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Lorlatinib Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Lorlatinib Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Lorlatinib Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Lorlatinib Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Lorlatinib Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Lorlatinib Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Lorlatinib Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Lorlatinib Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Lorlatinib Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Lorlatinib Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Lorlatinib Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Lorlatinib Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Lorlatinib Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Lorlatinib Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Lorlatinib Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Lorlatinib Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Lorlatinib Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Lorlatinib Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Lorlatinib Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Lorlatinib Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Lorlatinib Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Lorlatinib Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Lorlatinib Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Lorlatinib Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Lorlatinib Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Lorlatinib Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Lorlatinib Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Lorlatinib Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Lorlatinib Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Lorlatinib Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Lorlatinib Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Lorlatinib Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Lorlatinib Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Lorlatinib Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Lorlatinib Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Lorlatinib Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Lorlatinib Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Lorlatinib Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Lorlatinib Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Lorlatinib Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Lorlatinib Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Lorlatinib Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Lorlatinib Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Lorlatinib Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Lorlatinib Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Lorlatinib Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Lorlatinib Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Lorlatinib Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Lorlatinib Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Lorlatinib Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Lorlatinib Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Lorlatinib Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Lorlatinib Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Lorlatinib Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Lorlatinib Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Lorlatinib Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Lorlatinib Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Lorlatinib Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Lorlatinib Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Lorlatinib Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Lorlatinib Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Lorlatinib Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Lorlatinib Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Lorlatinib Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Lorlatinib Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Lorlatinib Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Lorlatinib Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Lorlatinib Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Lorlatinib Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Lorlatinib Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Lorlatinib Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Lorlatinib Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Lorlatinib Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Lorlatinib Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Lorlatinib Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Lorlatinib Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Lorlatinib Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Lorlatinib Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Lorlatinib Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Lorlatinib Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Lorlatinib Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Lorlatinib Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Lorlatinib Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Lorlatinib Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Lorlatinib Value Chain Analysis
  2. 9.1.1 Lorlatinib Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Lorlatinib Sales Mode & Process
  6. 9.2 Lorlatinib Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Lorlatinib Distributors
  9. 9.2.3 Lorlatinib Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst